- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07944378
A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia (LOHKALT)
A Phase IV, Multicentre, Non-comparative, Open-label Study Evaluating the Safety and Effectiveness of Lokelma (Sodium Zirconium Cyclosilicate [SZC]) Administered Orally for the Treatment of Indian Patients With Hyperkalaemia
This is a Phase IV, multicentre, open-label, non-comparative study evaluating Lokelma (sodium zirconium cyclosilicate, SZC) in approximately 100 Indian adults with mild to moderate hyperkalaemia.
연구 개요
상세 설명
The primary objective is to assess safety through treatment-emergent adverse events, serious adverse events and discontinuations due to adverse events. Secondary objectives are to assess effectiveness of Lokelma through serum potassium reduction, achievement and maintenance of normokalaemia, while an exploratory objective focuses on continuation or initiation of RAAS inhibitor therapy. Each participant is followed for approximately 3.5 months, including treatment and a safety follow-up seven days after the final dose.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: AstraZeneca Clinical Study Information Center
- 전화번호: 1-877-240-9479
- 이메일: information.center@astrazeneca.com
연구 장소
-
-
-
Ahmedabad, 인도, 380052
- 모병
- Research Site
-
Ahmedabad, 인도, 380013
- 모병
- Research Site
-
Kolkata, 인도, 700020
- 모병
- Research Site
-
Secunderabad, 인도, 500003
- 모병
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
• Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Participants with mild to moderate hyperkalaemia- the potassium values between 5.1 to 6.4 mmol/L inclusive, at screening (Day 0)
- Ability to have repeated blood draws or effective venous catheterisation.
- Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. i) FOCBP must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening. The female participants should be on stable on their chosen method of birth control for minimum of one month before entering the study and willing to remain on the birth control until 7 days after the last dose. ii) Female participants who are surgically sterile or those who are post-menopausal (if they have been amenorrhoeic for 12 months prior to the planned date of screening without an alternative medical cause) are not considered to be of child-bearing potential.
- Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
As judged by the investigator, any evidence of oedema which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Patients undergoing haemodialysis or a prospective candidate for haemodialysis.
- Pseudo hyperkalaemia signs and symptoms, such as excessive fist clenching haemolysed blood specimen, severe leucocytosis or thrombocytosis.
- Participants with a life expectancy of < 12 months.
- Participants who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the participants' tasks associated with the protocol.
- Women who are pregnant, lactating, or planning to become pregnant.
- Participants with diabetic ketoacidosis.
- Presence of any condition which, in the opinion of the investigator, places the participant at undue risk.
- Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
- Participants with cardiac arrhythmias requiring immediate treatment.
- Participants with history of QT prolongation associated with other medications that required discontinuation of that medication.
- Participants with congenital long QT syndrome.
- Participants treated with lactulose, rifaximin or other non-absorbed antibiotics for hyperammonaemia within the last 7 days.
- Participants treated with resins (such as sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.
- Participants treated with SPS or SZC (microporous, fractionated, protonated zirconium silicate), CPS or patiromer within the last 7 days.
- Known hypersensitivity or previous anaphylaxis to SZC or to components or any of the excipients of the product.
- Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
- Prior (within last 1 month) and ongoing participation in another clinical trial, observational study, and real-world evidence study.
- Positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody, at screening.
- Known to have tested positive for HIV.
- Documented glomerular filtration rate < 15 mL/min/1.73 m2 within 90 days before study entry.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Intervention
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of TEAEs, SAEs, and DAEs.
기간: Day 86
|
Number and proportion of participants with TEAEs SAEs, and DAEs. Incidence rates summarised by patients with events per 100 patient-years. |
Day 86
|
|
Causal relationship of TEAEs, SAEs, and DAEs
기간: Day 86
|
Nature, intensity and causal relationship of TEAEs, SAEs, and DAEs |
Day 86
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Exponential rate of change in S-K values
기간: Day 4
|
Rate of Change in S-K values |
Day 4
|
|
Proportion of participants who achieve normokalaemia
기간: Day 4
|
Number of study subjects achieving normal potassium levels |
Day 4
|
|
Mean change and mean percent change from baseline in S-K values
기간: Day 86
|
Mean change and mean percent change from baseline in S-K values over time until EOT |
Day 86
|
|
Proportions of participants maintaining normokalaemia
기간: Day 86
|
Number participants maintaining normal potassium levels at EOT |
Day 86
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- D9480L00025
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .